SCHEMBL402452

SCHEMBL402452

COC(=O)c1ccc2c(=O)[nH]c(Cc3ccc(Cl)c(Cl)c3)nc2c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.57
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HTT P42858 2/20 0.56
RAB9A P51151 1/20 0.56
RNASEH1 O60930 1/20 0.51
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HSD17B10 Q99714 1/20 0.50
POLB P06746 2/20 0.49
RECQL P46063 1/20 0.49
USP2 O75604 1/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 1/20 0.42
PARP1 P09874 1/20 0.42
CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401655 0.87 PDE5A (0.74) PDE5AKDM4ERNASEH1MAPTMEN1
SCHEMBL37938 0.86 PDE5A (0.77) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL404601 0.85 KDM4E (0.56) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL399659 0.82 PDE5A (0.59) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL2118620 0.82 KDM4E (0.72) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL31483754 0.82 KDM4E (0.72) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL403045 0.81 PDE5A (0.71) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL400571 0.80 ALDH1A1 (0.56) PDE5AKDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL17888977 0.80 RNASEH1 (0.55) PDE5AKDM4ERNASEH1MAPTKMT2A
SCHEMBL10262840 0.79 KDM4E (0.62) PDE5AKDM4EALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A PDE5A 3/4885KDM4E 2869/4885ALDH1A1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.